Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Approves Padcev, Entresto’s Hypertension Use, Lilly’s RET Inhibitor and More
Japan’s Ministry of Health, Labor and Welfare (MHLW) on September 27 approved a batch of new medicines and additional indications including Astellas Pharma’s antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) and the label expansion of Novartis’ Entresto (sacubitril valsartan sodium hydrate)…
To read the full story
Related Article
- Lilly’s RET Inhibitor, Pfizer’s Oral JAK Drug Make Japan Debut
December 14, 2021
- November Listing OK’ed for Cibinqo, Retevmo, Padcev and More
November 17, 2021
- Astellas’ Padcev, Pfizer’s JAK Inhibitor, AZ’s Lupus Drug Clear PAFSC Panel
September 7, 2021
- Entresto Clears MHLW Panel with Strings Attached, It’s Not a 1st Choice Drug
September 6, 2021
- MHLW Panel Shelves Decision on Entresto’s Hypertension Use, Clears Otsuka’s Eczema Med and More
August 31, 2021
- Lilly’s Selpercatinib Clears Key Panel, in Line for September Approval
August 2, 2021
REGULATORY
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
- CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
- AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…